Equities Analysts Offer Predictions for LLY FY2027 Earnings

Eli Lilly and Company (NYSE:LLY) – Analysts at Erste Group Bank lifted their FY2027 earnings per share (EPS) estimates for Eli Lilly and Company in a research note issued to investors on Wednesday, October 21st. Erste Group Bank analyst H. Engel now expects that the company will earn $47.77 per share for the year, up from their prior forecast of $47.30. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $33.56 per share.

Several other equities analysts also recently weighed in on LLY. Wall Street Zen downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Saturday, October 17th. Bank of America increased their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research note on Friday, July 10th. HSBC raised their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the company a “reduce” rating in a research report on Thursday, September 10th. UBS Group set a $1,376.00 target price on shares of Eli Lilly and Company in a research note on Friday, August 7th. Finally, Morgan Stanley upped their target price on shares of Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $1,317.93.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,308.21 on Friday. Eli Lilly and Company has a 12 month low of $806.02 and a 12 month high of $1,321.21. The stock has a market cap of $1.23 trillion, a price-to-earnings ratio of 43.90, a PEG ratio of 1.69 and a beta of 0.46. The company’s 50 day moving average is $1,184.78 and its two-hundred day moving average is $1,119.15. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the previous year, the firm earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Maseco LLP grew its position in shares of Eli Lilly and Company by 466.7% during the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after purchasing an additional 28 shares in the last quarter. Marshall & Sterling Wealth Advisors Inc. increased its holdings in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares during the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth about $42,000. Caitlin John LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter worth about $64,000. Finally, IMG Wealth Management Inc. lifted its position in shares of Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock worth $72,000 after buying an additional 50 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. The trade was a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock valued at $15,958,170. Corporate insiders own 0.14% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly broke ground on a planned $5 billion manufacturing facility in Goochland County, Virginia. The fully integrated site will produce active pharmaceutical ingredients and finished medicines, including next-generation cancer treatments, and is expected to create 650 jobs. The project is part of Lilly’s more than $50 billion U.S. manufacturing expansion and should increase future production capacity. Lilly Richmond manufacturing facility
• Positive Sentiment: Analysts continue to highlight Lilly’s dominant position in cardiometabolic and incretin medicines, with Mounjaro and Zepbound driving expectations for explosive growth. Comparisons with Amgen and Bristol Myers Squibb reinforce Lilly’s strong exposure to the expanding GLP-1 market. Amgen versus Eli Lilly
• Positive Sentiment: New international agreements involving Mubadala Bio and Abu Dhabi-based operations are intended to expand packaging, logistics and contract-manufacturing capabilities for Lilly’s weight-loss medicines, potentially improving supply-chain flexibility and market access. Lilly and Mubadala Bio agreement
• Neutral Sentiment: Lilly is scheduled to release quarterly results soon. Investor focus will be on demand for Mounjaro and Zepbound, manufacturing capacity, guidance and whether volume growth can offset pricing pressure.
• Negative Sentiment: Previews warn that third-quarter earnings could decline and suggest Lilly may lack the usual catalysts for an earnings beat. Recent results showed revenue growth of about 48% alongside a 60% increase in medicine volume, but realized prices fell 13%, raising concerns about the sustainability and profitability of growth. Lilly earnings preview

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.